NYSE:DVA DaVita (DVA) Stock Price, News & Analysis $174.71 -8.43 (-4.60%) Closing price 03:59 PM EasternExtended Trading$174.48 -0.22 (-0.13%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About DaVita Stock (NYSE:DVA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get DaVita alerts:Sign Up Key Stats Today's Range$174.32▼$183.7850-Day Range$174.21▼$240.5952-Week Range$101.00▼$247.49Volume788,834 shsAverage Volume682,389 shsMarket Capitalization$11.15 billionP/E Ratio14.30Dividend YieldN/APrice Target$233.43Consensus RatingModerate Buy Company Overview DaVita Inc. (NYSE: DVA) is a healthcare company focused primarily on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis services for people with chronic kidney failure, including in-center hemodialysis and home-based dialysis options. Its services also include clinical care, education, nutrition support and other resources intended to help patients manage kidney disease. DaVita also provides broader kidney-care services, including chronic kidney disease management, care coordination and support for patients who may be candidates for kidney transplantation. The company operates dialysis centers and related care programs primarily in the United States, with additional operations in selected international markets. The company traces its history to 1979, when it was established as Medical Ambulatory Care, and adopted the DaVita name in 2000. Javier Rodriguez serves as DaVita’s chief executive officer. The company’s operations are centered on its kidney-care platform and its network of clinicians, physicians and other healthcare professionals.AI Generated. May Contain Errors. Read More DaVita Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks98th Percentile Overall ScoreDVA MarketRank™: DaVita scored higher than 98% of companies evaluated by MarketBeat, and ranked 18th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingDaVita has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 4 buy ratings, 3 hold ratings, and no sell ratings.Upside PotentialDaVita has a consensus price target of $233.43, representing about 33.6% upside from its current price of $174.71.Amount of Analyst CoverageDaVita has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about DaVita's stock forecast and price target. Earnings and Valuation4.4 / 5Proj. Earnings Growth18.39% Earnings GrowthEarnings for DaVita are expected to grow by 18.39% in the coming year, from $14.57 to $17.25 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DaVita is 14.30, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.94.Price to Earnings Ratio vs. SectorThe P/E ratio of DaVita is 14.30, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.98.Price to Earnings Growth RatioDaVita has a PEG Ratio of 0.48. PEG Ratios below 1 indicate that a company could be undervalued.Read more about DaVita's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.87% of the float of DaVita has been sold short.Short Interest Ratio / Days to CoverDaVita has a short interest ratio ("days to cover") of 6.75.Change versus previous monthShort interest in DaVita has recently decreased by 8.08%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDaVita does not currently pay a dividend.Dividend GrowthDaVita does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.88 News SentimentDaVita has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for DaVita this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for DVA on MarketBeat in the last 30 days. This is a decrease of -85% compared to the previous 30 days.MarketBeat Follows2 people have added DaVita to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, DaVita insiders have not sold or bought any company stock.Percentage Held by Insiders1.90% of the stock of DaVita is held by insiders.Percentage Held by Institutions90.12% of the stock of DaVita is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about DaVita's insider trading history. Receive DVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DaVita and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DVA Stock News HeadlinesDaVita Inc. (NYSE:DVA) Given Consensus Recommendation of "Moderate Buy" by BrokeragesSeptember 23 at 3:29 AM | americanbankingnews.com3 Surging Stocks That Don’t Need the AI Boom to Keep WinningDaVita, Franklin Resources, and Archer Daniels Midland have each gained more than 30% year to date in 2026, offering investors diversification away from AI-driven stock market gains.September 21 at 9:10 AM | marketbeat.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.September 24 at 1:00 AM | Porter & Company (Ad)Investors Buy Large Volume of DaVita Call Options (NYSE:DVA)September 20, 2026 | americanbankingnews.comDaVita slides as recent rally cools without an obvious fresh catalystSeptember 17, 2026 | quiverquant.comQDaVita jumps 10% as AI strategy’s healthcare pick rides stronger guidanceSeptember 17, 2026 | au.finance.yahoo.comFinancial Analysis: OPKO Health (NASDAQ:OPK) vs. DaVita (NYSE:DVA)September 16, 2026 | americanbankingnews.comBofA Adjusts Price Target on DaVita to $180 From $170September 15, 2026 | finance.yahoo.comSee More Headlines DVA Stock Analysis - Frequently Asked Questions How have DVA shares performed this year? DaVita's stock was trading at $113.74 at the beginning of 2026. Since then, DVA stock has increased by 53.6% and is now trading at $174.7070. How were DaVita's earnings last quarter? DaVita Inc. (NYSE:DVA) issued its quarterly earnings data on Tuesday, August, 4th. The company reported $4.02 earnings per share for the quarter, beating the consensus estimate of $3.88 by $0.14. The firm's quarterly revenue was up 5.2% on a year-over-year basis. Read the conference call transcript. Does DaVita have any subsidiaries? The following companies are subsidiaries of DaVita: Northwest Physicians Network, Purity Dialysis, Family Health Care of Central Florida, Healthcare Partners, Gambro Healthcare, Aberdeen Dialysis LLC, Accountable Kidney Care LLC, and more. Who are DaVita's major shareholders? Top institutional investors of DaVita include Berkshire Hathaway Inc (45.27%), BlackRock Inc. (3.86%), Bank of America Corp DE (1.02%) and Bank of New York Mellon Corp (0.71%). Insiders that own company stock include Javier Rodriguez, Michael David Staffieri, Joel Ackerman, Kathleen Alyce Waters, James O Hearty and Barbara J Desoer. View institutional ownership trends. How do I buy shares of DaVita? Shares of DVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of DaVita own? Based on aggregate information from My MarketBeat watchlists, some other companies that DaVita investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings8/04/2026Today9/24/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 DVA's financial health is in the Red zone, according to TradeSmith. DVA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryHealthcare Services Current SymbolNYSE:DVA CIK927066 Webwww.davita.com Phone(310) 536-2668Fax302-636-5454Employees78,000Year Founded1994Price Target and Rating Average Price Target for DaVita$233.43 High Price Target$270.00 Low Price Target$215.00 Potential Upside/Downside+33.6%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$12.22 Trailing P/E Ratio14.35 Forward P/E Ratio11.99 P/E Growth0.48Net Income$746.80 million Net Margins6.05% Pretax Margin10.48% Return on Equity-217.63% Return on Assets5.07% Debt Debt-to-Equity RatioN/A Current Ratio1.47 Quick Ratio1.41 Sales & Book Value Annual Sales$13.64 billion Price / Sales0.82 Cash Flow$20.65 per share Price / Cash Flow8.46 Book Value($5.29) per share Price / Book-33.03Miscellaneous Outstanding Shares63,800,000Free Float62,588,000Market Cap$11.15 billion OptionableOptionable Beta0.83 Social Links 10 Best Stocks to Own - Fall 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NYSE:DVA) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThey're shrinking your dollars every single monthSince 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...American Alternative | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DaVita Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DaVita With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
